SK to pay up to $571M in new radiopharma deal; Aslan lets go of all employees
Plus, news about Aclaris, OMERS Life Sciences, Draupnir Bio, Pharnext and Actuate:
SK Biopharmaceuticals licenses Full-Life’s radiopharma drug: The deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
